title: [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
abstract: The efficacy of an intravenous 5-HT3 antagonist (granisetron) and four oral 5-HT3 antagonists (granisetron, ondansetron, tropisetron and ramosetron) on chemotherapy-induced emesis were investigated in 21 gynecologic cancer patients (63 courses). The severity of emesis after chemotherapy was classified in 4 grades (0: none, 1: slight loss of appetite, 2: severe loss of appetite, but tolerable, and 3: untolerable). The effect of 5-HT3 antagonists was judged by both the score for the severity of the emesis and the frequency of vomiting. The four oral 5-HT3 antagonists were almost the same in efficacy for 5 days after chemotherapy. Oral 5-HT3 antagonists were almost equipotent to intravenous granisetron for JT (paclitaxel + carboplatin) therapy or T (paclitaxel) therapy for 5 days after chemotherapy. However, they were ineffective for CAP (cisplatin + adriamycin + cyclophosphamide) therapy. From these results, oral 5-HT3 antagonists were proved to have a sufficient anti emetic effect after chemotherapy in cases of JT or T therapy. However, in cases of CAP therapy, intravenous 5-HT3 antagonists were thought to be preferable for the control of emesis due to chemotherapy.
authors.affiliation: Dept. of Obstetrics and Gynecology, School of Medicine, Sapporo Medical University.
authors.forename: S
authors.initials: S
authors.lastname: Ishioka
authors.forename: S
authors.initials: S
authors.lastname: Sagae
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Kiya
authors.forename: M
authors.initials: M
authors.lastname: Sugimura
authors.forename: N
authors.initials: N
authors.lastname: Akutagawa
authors.forename: K
authors.initials: K
authors.lastname: Umemura
authors.forename: E
authors.initials: E
authors.lastname: Ito
authors.forename: R
authors.initials: R
authors.lastname: Kudo
mesh_terms: D000284:Administration, Oral; D000932:Antiemetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D017294:Ondansetron / Q000627:therapeutic use*; D017239:Paclitaxel / Q000009:adverse effects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D000077526:Tropisetron; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D001562:Benzimidazoles; D016190:Carboplatin; D002945:Cisplatin; D003520:Cyclophosphamide; D004317:Doxorubicin; D017829:Granisetron; D007211:Indoles; D017294:Ondansetron; D017239:Paclitaxel; D012702:Serotonin Antagonists; D000077526:Tropisetron; C071315:ramosetron